Expertise in
7
conditions

Hongqian Q. Guo

No. 321 Zhongshan Road, 
Nanjing, CN 
Expertise in
7
conditions
No. 321 Zhongshan Road, 
Nanjing, CN 

Overview

Hongqian Guo practices practicing medicine in Nanjing, China.

Guo is highly rated in 7 conditions, according to our data. Their clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Bladder Cancer, Prostatectomy, and Nephrectomy.

They are actively involved in clinical research, co-authoring 380 peer reviewed articles and participating in 3 clinical trials.

Locations

No. 321 Zhongshan Road, Nanjing, 210008, China
Other Locations
321 Zhongshan Road, Nanjing, 210008, China
No. 321 Zhongshan Road, 210008, Nanjing, China
72 Guangzhou Road, Nanjing, 210008, China
No. 321 Zhongshan Road, Nanjing, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drugs: TQB2450, Anlotinib, Sunitinib
Study Phase: Phase 3
View 2 Less Clinical Trials

380 Total Publications

ASO Visual Abstract: A Pathology-Based Model for Postoperative Recurrence or Metastasis Prediction and Adjuvant Immunotherapy Implications of Clear-Cell Renal Cell Carcinoma: A Multicenter, Retrospective Study.
ASO Visual Abstract: A Pathology-Based Model for Postoperative Recurrence or Metastasis Prediction and Adjuvant Immunotherapy Implications of Clear-Cell Renal Cell Carcinoma: A Multicenter, Retrospective Study.
Journal: Annals of surgical oncology
Published: August 21, 2026

Frequently Asked Questions about Hongqian Q. Guo

Is Hongqian Q. Guo a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Hongqian Q. Guo is classified as an Distinguished expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hongqian Q. Guo participate in research or clinical trials?

Yes. Hongqian Q. Guo has published 380 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Hongqian Q. Guo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Guo's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile